Eylea

Aflibercept, the active ingredient in Eylea, is a VEGF inhibitor presented as a 40 mg/ml solution for intravitreal use. It is used to treat various eye conditions in adults, including neovascular age-related macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion. GNH USA supplies Eylea as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Eylea is a solution that is injected into the eye to treat specific eye diseases in adults. The active substance, aflibercept, blocks the activity of VEGF-A and PlGF, which are involved in the formation of new blood vessels and vascular permeability.

Eylea is used to treat various eye conditions related to abnormal blood vessel growth and fluid leakage in the retina. It is indicated for the following conditions:

- Neovascular age-related macular degeneration (wet AMD): Helps to stabilize and improve vision loss related to wet AMD. - Diabetic macular edema (DME): Reduces vision loss due to fluid leakage in the retina caused by diabetes. - Macular edema secondary to retinal vein occlusion (RVO): Improves vision by reducing fluid leakage in the retina due to blocked blood vessels. - Myopic choroidal neovascularization (mCNV): Prevents vision loss by inhibiting abnormal blood vessel growth in the retina.

Eylea may cause side effects, which can be categorized as common or serious.

Common Side Effects: - Eye pain or redness at the injection site. - Conjunctival hemorrhage (small blood spots on the white of the eye). - Increased intraocular pressure. - Floaters in the vision. - Cataracts. - Vitreous detachment.

Serious or Rare Side Effects: - Endophthalmitis (severe eye infection). - Retinal detachment or tears. - Intraocular inflammation. - Increased risk of stroke or heart attack. - Severe vision loss.

Eylea should be used with caution and under the supervision of a healthcare professional. Important precautions include:

- Infection risk: The injection site must be properly sterilized to prevent infection. - Pre-existing conditions: Inform your doctor if you have a history of eye infections, inflammation, or glaucoma. - Allergic reactions: Seek immediate medical attention if you experience signs of an allergic reaction. - Pregnancy and breastfeeding: The safety of Eylea during pregnancy and breastfeeding has not been established. - Storage: Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Eylea may interact with other medications, which can be categorized as major or moderate.

Major Interactions (Avoid): - Other anti-VEGF therapies: Concurrent use may increase the risk of adverse effects. - Immunosuppressants: May enhance the risk of infections. - Blood thinners: Increased risk of bleeding complications.

Moderate Interactions (Monitor Closely): - Corticosteroids: May increase the risk of cataracts or glaucoma. - Nonsteroidal anti-inflammatory drugs (NSAIDs): May enhance the risk of bleeding. - Antihypertensives: May require dose adjustment due to changes in blood pressure.